Bulgaria
Tuberculosis profile
| High MDR-TB burden |
Population  2013 7.2 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.15 (0.15–0.15) 2.1 (2–2.1)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.01 (0.01–0.02)
Prevalence  (includes HIV+TB) 2.7 (1.1–5) 37 (15–69)
Incidence  (includes HIV+TB) 2.1 (2–2.4) 29 (27–33)
Incidence (HIV+TB only) <0.01 (<0.01–<0.01) 0.08 (0.08–0.09)
Case detection, all forms (%) 91 (81–98)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 2.3 (1.3–3.8) 23 (17–31)
MDR-TB cases among notified pulmonary
TB cases
28 (16–45) 50 (36–67)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 843   145
Pulmonary, clinically diagnosed 366   69
Extrapulmonary 471   36
       
Total new and relapse 1 930    
Previously treated, excluding relapses 2    
Total cases notified 1 932    
Among 1 930 new and relapse cases:
146 (8%) cases aged under 15 years; male:female ratio: 2.0
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 619 (73%) 109 (43%) 728
Laboratory-confirmed RR-/MDR-TB cases     37
Patients started on MDR-TB treatment     19
TB/HIV 2013 Number (%)
TB patients with known HIV status 1 393 (72)
HIV-positive TB patients 4 (<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 0 (0)
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT 70  
Treatment success rate (%)
New and relapse cases registered in 2012 87
Previously treated cases, excluding relapse, registered in 2012 47
HIV-positive TB cases, all types, registered in 2012 33
RR-/MDR-TB cases started on second-line treatment in 2011 55
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 0.5
Culture (per 5 million population) 20.8
Drug susceptibility testing (per 5 million population) 8.3
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions) 13
% Funded domestically 68%
% Funded internationally 32%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-06-30 Data: www.who.int/tb/data